Literature DB >> 15694358

Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21.

Zheng-Nan Shen1, Keiichiro Nishida, Hideyuki Doi, Toshitaka Oohashi, Satoshi Hirohata, Toshifumi Ozaki, Aki Yoshida, Yoshifumi Ninomiya, Hajime Inoue.   

Abstract

We previously reported that 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), the most potent agonist for peroxisome proliferator-activated receptor gamma (PPAR gamma), induces apoptosis of human chondrosarcoma cell line OUMS-27. The current study aimed to explore the mechanism of 15d-PGJ(2)-induced apoptosis and inhibition of cell proliferation in OUMS-27 cells. The preliminary results of cDNA microarray analysis showed the down-regulation of anti-apoptotic Bcl-xL and up-regulation of pro-apoptotic Bax in the process of 15d-PGJ(2)-induced apoptosis. These changes were further confirmed at mRNA and protein levels by RT-PCR and Western blot analysis, respectively. Among cyclin-dependent kinase inhibitors, p21 was induced and up-regulated by 15d-PGJ(2), but p16 and p27 were not changed, suggesting that the involvement of p21 in inhibition of cell proliferation. Activation of caspase-3 by 15d-PGJ(2) was partly, but not completely, blocked by PPAR gamma antagonist (GW9662) suggesting the 15d-PGJ(2) exerted its effect by PPAR gamma-dependent and -independent pathways. Interestingly, immunohistochemical study on human chondrosarcoma samples revealed that Bcl-xL is frequently expressed by tumor cells. The results of the current study suggest that the potential ability of 15d-PGJ(2) in regulation of cell cycle and inhibition of Bcl-xL expression might be beneficial in the development of novel pharmacological agents for chondrosarcoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694358     DOI: 10.1016/j.bbrc.2004.12.186

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Therapeutic Implications of PPARgamma in Human Osteosarcoma.

Authors:  Eric R Wagner; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Wenli Zhang; Qiong Shi; Qing Luo; Xiaoji Luo; Bo Liu; Jinyong Luo; Farbod Rastegar; Connie J He; Yawen Hu; Barrett Boody; Hue H Luu; Tong-Chuan He; Zhong-Liang Deng; Rex C Haydon
Journal:  PPAR Res       Date:  2010-02-16       Impact factor: 4.964

3.  Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells.

Authors:  Mei Ming; Jie-Ping Yu; Xiang-Zhi Meng; Yan-Hong Zhou; Hong-Gang Yu; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

4.  Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.

Authors:  Ulf Lützen; Yi Zhao; Katja Lucht; Maaz Zuhayra; Marlies Marx; Ingolf Cascorbi; Juraj Culman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-23       Impact factor: 3.000

5.  siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.

Authors:  Dae Won Kim; Kyung-Ok Kim; Mike J Shin; Jung Hee Ha; Sung Wook Seo; Jay Yang; Francis Y Lee
Journal:  Mol Cancer       Date:  2009-05-15       Impact factor: 27.401

6.  Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells.

Authors:  Dong Wan Kang; Chang Hwa Choi; Ji Yeon Park; Soo Kyung Kang; Yong Keun Kim
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

7.  Proximal humerus chondrosarcoma in a young male patient.

Authors:  Răzvan Ene; Florin Cătălin Cîrstoiu; Mihai Nica; Zsombor Alpár Pánti; Corina Panaitescu; Elisa Popescu; Adrian Vasile Dumitru; Irina Anca Eremia; Adrian Cursaru; Dragoş Ene
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

8.  Cytotoxicity of 15-deoxy-Δ(12,14)-prostaglandin J(2) through PPARγ-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma.

Authors:  Megumi Fujita; Chiaki Tohji; Yoko Honda; Yasuhiro Yamamoto; Tsutomu Nakamura; Tatsurou Yagami; Motohiro Yamamori; Noboru Okamura
Journal:  Int J Med Sci       Date:  2012-09-04       Impact factor: 3.738

9.  Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.

Authors:  Vivek Subbiah; Robert E Brown; Jamie Buryanek; Jonathan Trent; Avi Ashkenazi; Roy Herbst; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-08-20       Impact factor: 6.009

10.  Chondrosarcoma and peroxisome proliferator-activated receptor.

Authors:  K Nishida; T Kunisada; Z N Shen; Y Kadota; K Hashizume; T Ozaki
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.